Search This Blog

Monday, September 23, 2024

Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT says

  Novo Nordisk's (NOVOb.CO) chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.

https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-faces-us-congressional-grilling-over-price-weight-loss-drugs-ft-2024-09-23/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.